186 related articles for article (PubMed ID: 31412748)
1. Decreased Expression of Semaphorin 3A and Semaphorin 7A Levels and Its Association with Systemic Lupus Erythematosus.
Wang P; Mao YM; Liu LN; Zhao CN; Li XM; Pan HF
Immunol Invest; 2020 Feb; 49(1-2):69-80. PubMed ID: 31412748
[TBL] [Abstract][Full Text] [Related]
2. Semaphorin-3A,
Liu LN; Wang P; Zou YF; Xu Z; Cheng J; Zhang Y; Hu W; Pan HF
Autoimmunity; 2019 Jun; 52(4):161-167. PubMed ID: 31394943
[No Abstract] [Full Text] [Related]
3. Assessment of semaphorin 3A and semaphorin 7A levels in primary Sjogren's syndrome.
Urhan E; Urhan AC; Dogan HO; Sahin A
Rheumatol Int; 2023 Jun; 43(6):1087-1092. PubMed ID: 36030414
[TBL] [Abstract][Full Text] [Related]
4. Gene expression of semaphorin-3A, semaphorin-7A, neuropilin-1, plexin-C1, and β1 integrin in treated-multiple sclerosis patients.
Shapoori S; Mosayebi G; Ebrahimi Monfared M; Ghazavi A; Khansarinejad B; Farahani I; Ganji A
Neurol Res; 2020 Sep; 42(9):783-788. PubMed ID: 32497464
[TBL] [Abstract][Full Text] [Related]
5. [Association of Semaphorin 3A with thrombocytopenia in systemic lupus erythematosus].
Guo Q; Ma XX; Gao H; Shi LJ; Zhong YC; Xie LF; Shao M; Zhang XW
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Oct; 52(5):892-896. PubMed ID: 33047725
[TBL] [Abstract][Full Text] [Related]
6. [Expression and Clinical Significance of Semaphorin 3A in serum and mononuclear cells in patients with systemic lupus erythematosus].
Gao H; Ma XX; Guo Q; Zou YD; Zhong YC; Xie LF; Shao M; Zhang XW
Zhonghua Yi Xue Za Zhi; 2017 Feb; 97(5):370-374. PubMed ID: 28219195
[No Abstract] [Full Text] [Related]
7. Semaphorin 3A is a marker for disease activity and a potential immunoregulator in systemic lupus erythematosus.
Vadasz Z; Haj T; Halasz K; Rosner I; Slobodin G; Attias D; Kessel A; Kessler O; Neufeld G; Toubi E
Arthritis Res Ther; 2012 Jun; 14(3):R146. PubMed ID: 22697500
[TBL] [Abstract][Full Text] [Related]
8. Low Urine Secretion of Semaphorin3A in Lupus Patients with Proteinuria.
Doron R; Merav L; Nasrin E; Adi SD; Elias T; Gleb S; Itzhak R; Michael R; Zahava V
Inflammation; 2022 Apr; 45(2):603-609. PubMed ID: 34562225
[TBL] [Abstract][Full Text] [Related]
9. Expression of semaphorin 3A, semaphorin 7A and their receptors in multiple sclerosis lesions.
Costa C; Martínez-Sáez E; Gutiérrez-Franco A; Eixarch H; Castro Z; Ortega-Aznar A; Ramón Y Cajal S; Montalban X; Espejo C
Mult Scler; 2015 Nov; 21(13):1632-43. PubMed ID: 26432853
[TBL] [Abstract][Full Text] [Related]
10. Semaphorin 3A - a marker for disease activity and a potential putative disease-modifying treatment in systemic lupus erythematosus.
Vadasz Z; Toubi E
Lupus; 2012 Oct; 21(12):1266-70. PubMed ID: 22875653
[TBL] [Abstract][Full Text] [Related]
11. Semaphorin 3A: an immunoregulator in systemic sclerosis.
Rimar D; Nov Y; Rosner I; Slobodin G; Rozenbaum M; Halasz K; Haj T; Jiries N; Kaly L; Boulman N; Vadasz Z
Rheumatol Int; 2015 Oct; 35(10):1625-30. PubMed ID: 25895648
[TBL] [Abstract][Full Text] [Related]
12. Circulating Semaphorin 4D as a Marker for Predicting Radiographic Progression in Patients with Rheumatoid Arthritis.
Ha YJ; Han DW; Kim JH; Chung SW; Kang EH; Song YW; Lee YJ
Dis Markers; 2018; 2018():2318386. PubMed ID: 30538782
[TBL] [Abstract][Full Text] [Related]
13. Serum semaphorin 7A is associated with the risk of acute atherothrombotic stroke.
You T; Zhu Z; Zheng X; Zeng N; Hu S; Liu Y; Ren L; Lu Q; Tang C; Ruan C; Zhang Y; Zhu L
J Cell Mol Med; 2019 Apr; 23(4):2901-2906. PubMed ID: 30729666
[TBL] [Abstract][Full Text] [Related]
14. Elevated plasma midkine and pleiotrophin levels in patients with systemic lupus erythematosus.
Wu GC; Yuan H; Pan HF; Ye DQ
Oncotarget; 2017 Jun; 8(25):40181-40189. PubMed ID: 27903979
[TBL] [Abstract][Full Text] [Related]
15. Semaphorin 7A as a potential immune regulator and promising therapeutic target in rheumatoid arthritis.
Xie J; Wang H
Arthritis Res Ther; 2017 Jan; 19(1):10. PubMed ID: 28109308
[TBL] [Abstract][Full Text] [Related]
16. A regulatory role for CD72 expression on B cells in systemic lupus erythematosus.
Vadasz Z; Haj T; Balbir A; Peri R; Rosner I; Slobodin G; Kessel A; Toubi E
Semin Arthritis Rheum; 2014 Jun; 43(6):767-71. PubMed ID: 24461079
[TBL] [Abstract][Full Text] [Related]
17. Semaphorin 4A as a Potential Biomarker for Diagnosis of Systemic Lupus Erythematosus.
He R; Tan X; Xiang J; Zhu J; Jiang Y; Liu W; Li Y; Guo B; Xing Y
Immunol Invest; 2023 Jan; 52(1):104-116. PubMed ID: 36239661
[TBL] [Abstract][Full Text] [Related]
18. Differential expression of sema3A and sema7A in a murine model of multiple sclerosis: Implications for a therapeutic design.
Gutiérrez-Franco A; Costa C; Eixarch H; Castillo M; Medina-Rodríguez EM; Bribián A; de Castro F; Montalban X; Espejo C
Clin Immunol; 2016 Feb; 163():22-33. PubMed ID: 26686462
[TBL] [Abstract][Full Text] [Related]
19. Expression of circulating Semaphorin3A and its association with inflammation and bone destruction in rheumatoid arthritis.
Gao H; Ma XX; Guo Q; Xie LF; Zhong YC; Zhang XW
Clin Rheumatol; 2018 Aug; 37(8):2073-2080. PubMed ID: 29656374
[TBL] [Abstract][Full Text] [Related]
20. Association of Immune Semaphorins with COVID-19 Severity and Outcomes.
Vargovic M; Papic N; Samadan L; Balen Topic M; Vince A
Biomedicines; 2023 Oct; 11(10):. PubMed ID: 37893159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
